These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 4369487)

  • 41. Immunization with inactivated poliovirus vaccine and attenuated type 3 poliovirus. II. Parallel vaccinations and cross-wise revaccination in school children with the Sabin and WM3 attenuated strains.
    Böttiger M
    J Pediatr; 1969 Aug; 75(2):273-80. PubMed ID: 4307564
    [No Abstract]   [Full Text] [Related]  

  • 42. Antibody to poliovirus in older children and young adults in Israel and the use of poliovaccines for the immunization of the seronegatives.
    Goldblum N; Kra-Oz Z; Swartz T
    Dev Biol Stand; 1979; 43():173-7. PubMed ID: 230108
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RESPONSE TO ONE DOSE OF TRIVALENT ORAL POLIOVACCINE IN CHILDREN PREVIOUSLY IMMUNISED WITH SALK VACCINE: A COMPARISON OF LIQUID VACCINE AND A CAPSULE PRESENTATION.
    BEALE AJ; DAVIES JR; THROWER AL
    Lancet; 1965 Apr; 1(7391):879-81. PubMed ID: 14272682
    [No Abstract]   [Full Text] [Related]  

  • 44. Evaluation of poliovirus antibody titers in orally vaccinated semi-captive chimpanzees in Uganda.
    Mugisha L; Pauli G; Opuda-Asibo J; Joseph OO; Leendertz FH; Diedrich S
    J Med Primatol; 2010 Apr; 39(2):123-8. PubMed ID: 20102460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
    Pliaka V; Kyriakopoulou Z; Markoulatos P
    Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of inactivated poliovirus vaccine in India.
    Krishnan R; Jadhav M; John TJ
    Bull World Health Organ; 1983; 61(4):689-92. PubMed ID: 6605215
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The use of immunomodulators to enhance postvaccinal immunity to experimental poliomyelitis].
    Bondarenko VI; Zadorozhnaia VI; Buraia TA; Gritsenko LN
    Mikrobiol Z; 1995; 57(6):41-5. PubMed ID: 8714398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Poliovirus antibody status and the response to trivalent oral poliovirus vaccine in Norwegian school children.
    Orstavik I; Flugsrud LB; Lahelle O
    Acta Paediatr Scand; 1968 Sep; 57(5):405-8. PubMed ID: 4974044
    [No Abstract]   [Full Text] [Related]  

  • 49. Clinical trial of concentrated inactivated polio vaccine in a simplified immunization program.
    Fillastre C; Emmou C; Meyran M; Schlumberger M; Guérin N
    Dev Biol Stand; 1981; 47():207-13. PubMed ID: 6262148
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunization with inactivated poliovirus vaccine and attenuated type 3 poliovirus. I. Vaccination with the WM3 strain in 20 families.
    Böttiger M; Lagercrantz R
    J Pediatr; 1969 Jul; 75(1):30-8. PubMed ID: 4307138
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparison of the immune response of the rabbit to virulent and attenuated strains of type 1 poliovirus.
    Gaudin OG; Viac J; Thouvenot D; Sohier R
    Bull World Health Organ; 1974; 50(6):479-5. PubMed ID: 4376464
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Poliomyelitis vaccination--choosing a wise policy.
    Salk J
    Pediatr Infect Dis J; 1987 Oct; 6(10):889-93. PubMed ID: 3696820
    [No Abstract]   [Full Text] [Related]  

  • 53. Is there a need for a change in poliomyelitis immunization policy?
    Sabin AB
    Pediatr Infect Dis J; 1987 Oct; 6(10):887-9. PubMed ID: 3696819
    [No Abstract]   [Full Text] [Related]  

  • 54. Poliovirus antibody differentiation. Methods and application for strain specific diagnosis in complications after oral vaccination.
    Kuwert E; Höher PG; Thraenhart O
    Zentralbl Bakteriol Orig A; 1976 Apr; 234(3):407-12. PubMed ID: 180727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
    Sawyer LA; McInnis J; Albrecht P
    Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
    [TBL] [Abstract][Full Text] [Related]  

  • 56. World wide experience with inactivated poliovirus vaccine.
    Bonnet MC; Dutta A
    Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response of children to a single dose of oral or inactivated polio vaccine.
    Magrath D; Bainton D; Freeman M
    Dev Biol Stand; 1981; 47():223-6. PubMed ID: 7227651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication.
    Cáceres VM; Sutter RW
    Clin Infect Dis; 2001 Aug; 33(4):531-41. PubMed ID: 11462191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mapping of type 1 poliovirus neutralization epitopes.
    Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
    Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Findings of virus-neutralizing antibodies against polioviruses in the population of Slovakia 9 and 12 years following introduction of immunization by attenuated polioviruses (author's transl)].
    Borská K; Mayerová A; Masár I; Svanigová L; Roda J; Lukácová V
    Bratisl Lek Listy; 1976 Apr; 65(4):400-6. PubMed ID: 183864
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.